Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: RPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.19% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.62M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 4 | Beta 0.83 | 52 Weeks Range 0.89 - 4.29 | Updated Date 07/9/2025 |
52 Weeks Range 0.89 - 4.29 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12197.76% |
Management Effectiveness
Return on Assets (TTM) -40.19% | Return on Equity (TTM) -71.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -57232154 | Price to Sales(TTM) 61.16 |
Enterprise Value -57232154 | Price to Sales(TTM) 61.16 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 42891400 | Shares Floating 22647519 |
Shares Outstanding 42891400 | Shares Floating 22647519 | ||
Percent Insiders 1.25 | Percent Institutions 69.46 |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. is a clinical-stage precision oncology company founded in 2016. It focuses on discovering and developing targeted therapeutics that exploit specific vulnerabilities of tumors with defects in DNA repair. Significant milestones include the clinical advancement of its lead programs and strategic collaborations with pharmaceutical companies.
Core Business Areas
- Drug Discovery: Repare Therapeutics identifies novel targets and develops small molecule inhibitors to address unmet medical needs in oncology, particularly for tumors with specific DNA repair defects.
- Clinical Development: The company advances its drug candidates through preclinical studies and clinical trials, focusing on safety and efficacy in selected patient populations.
- Commercialization: Repare seeks to commercialize its products, either independently or through partnerships with established pharmaceutical companies.
Leadership and Structure
Repare Therapeutics Inc. is led by a management team with experience in oncology drug development and commercialization. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Camonsertib: Camonsertib is a potent and selective oral small molecule inhibitor of ATR (ataxia telangiectasia and Rad3-related protein) kinase. It is currently undergoing clinical trials for advanced solid tumors with specific genomic alterations. Market share is not yet applicable as it's not approved. Competitors targeting ATR inhibitors include Vertex (VX-970).
- RP-6306: RP-6306 is a novel oral small molecule inhibitor of PKMYT1, which is a kinase that plays a key role in regulating cell cycle progression. It is in clinical trials for specific cancers. Competitors are limited as the target is relatively novel, but others may emerge in cell cycle inhibition.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with significant unmet need for targeted therapies that address specific tumor vulnerabilities. Precision oncology, which focuses on tailoring treatment to individual patients based on their tumor's genetic profile, is a growing area.
Positioning
Repare Therapeutics is positioned as a precision oncology company focused on DNA damage repair targets. Its competitive advantage lies in its proprietary drug discovery platform and its focus on identifying and developing novel inhibitors for specific targets.
Total Addressable Market (TAM)
The TAM for precision oncology and DNA damage repair therapies is estimated to be in the billions of dollars, growing as personalized medicine advances. Repare is positioned to capture a portion of this market by developing targeted therapies for specific patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Experienced management team
- Focus on precision oncology
- Strong scientific rationale for its targets
- Advancing drug candidates through clinical trials
Weaknesses
- Clinical trial risks
- Dependence on successful clinical trial outcomes
- High research and development costs
- Competition from larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies in oncology
- Partnerships with pharmaceutical companies
- Expansion of its drug discovery platform
- Expansion to other cancer types
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- AZN
- BMY
Competitive Landscape
Repare faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its focused approach, proprietary platform, and novel targets. Approval of its therapeutic could make it have more of a market share
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in its expanding pipeline and clinical trial advancements. Focus has been on R&D.
Future Projections: Future projections depend on clinical trial results, regulatory approvals, and commercial success. Analyst estimates will vary.
Recent Initiatives: Recent initiatives include advancing its lead programs through clinical trials, expanding its pipeline through drug discovery, and pursuing strategic collaborations.
Summary
Repare Therapeutics is a clinical-stage precision oncology company with a focus on DNA damage repair. They have an experienced management team and promising drug candidates. The company is currently pre-revenue and faces challenges with clinical trial risks and competition. Their future prospects depend on successful clinical trial outcomes and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Repare Therapeutics Inc. website
- SEC filings
- Company press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CFO, CEO & Director Mr. Steve Forte CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.